Form 4: Ironwood Pharmaceuticals Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
An Ironwood Pharmaceuticals executive sold 5,360 shares of Class A Common Stock to cover tax obligations related to vesting restricted stock units.
Summary
- Andrew Davis, SVP and Chief Business Officer at Ironwood Pharmaceuticals, sold 5,360 shares of Class A Common Stock on November 18, 2024, at a price of $4.08 per share.
- This sale was automatically executed to cover tax withholding obligations associated with the vesting of restricted stock units.
- The transaction was not a discretionary trade by the reporting person.
- Following the transaction, Mr. Davis beneficially owns 284,685 shares of Class A Common Stock.
- Mr. Davis also acquired 2,014 shares of Class A Common Stock under the company's employee stock purchase plan on June 30, 2024.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction related to executive compensation and tax obligations. It does not indicate any positive or negative sentiment.
Industry Context
This is a routine transaction related to executive compensation and tax obligations, which is common in publicly traded companies. It does not indicate any specific trend or issue within the pharmaceutical industry.
Comparison to Industry Standards
- Executive stock sales to cover tax obligations are a common practice across publicly traded companies, including those in the pharmaceutical sector.
- Similar transactions are frequently reported by executives at companies like AbbVie, Amgen, and Gilead Sciences, reflecting standard compensation practices.
- The number of shares sold and the price are within the typical range for such transactions, and do not indicate any unusual activity compared to industry peers.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.
- The sale does not affect the company's operations or financial health.
Key Dates
| Date | Description |
|---|---|
| 06/30/2024 | Andrew Davis acquired 2,014 shares of Class A Common Stock under the company's employee stock purchase plan. |
| 11/18/2024 | Andrew Davis sold 5,360 shares of Class A Common Stock to cover tax obligations. |
| 11/20/2024 | Date of filing of the SEC Form 4. |
Keywords
Ironwood Pharmaceuticals, insider trading, stock sale, tax obligations, restricted stock units, employee stock purchase plan, executive compensation, IRWD
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.